February 7th 2025
Completion of the phase 1 first-in-human trial revealed that iPSC-derived CAR natural killer cell therapy has potential for development across oncology.
Medical Crossfire®: Real World Strategies to Improve Therapeutic Durability and Outcomes in CLL
February 20, 2025
Register Now!
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Polatuzumab Vedotin Demonstrates Tolerable Safety Profile in Aggressive LBCLs
August 25th 2023Data indicate that replacement of vincristine with polatuzumab vedotin in combination with etoposide, prednisone, cyclophosphamide, doxorubicin, and rituximab should be further explored in large B-cell lymphoma.
FDA Issues CRL for Denileukin Diftitox in R/R Cutaneous T-Cell Lymphoma
July 31st 2023The regulatory agency requests enhanced product testing and additional controls in their market application review of denileukin diftitox for the treatment of those with relapsed/refractory cutaneous T-cell lymphoma.